Nobori umirolimus-eluting stent versus Xience/Promus everolimus-eluting stent in patients in Japan

Trial Profile

Nobori umirolimus-eluting stent versus Xience/Promus everolimus-eluting stent in patients in Japan

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Umirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2015 Effects of stent overlap on 2-year clinical outcomes in 2528 patients presented at the ESC Congress 2015: Annual Congress of the European Society of Cardiology.
    • 27 May 2015 New trial record
    • 20 Nov 2013 One-year results in a subset of patients with diabetes milletus presented at the 86th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top